Acceptance of Overseas Clinical Trial Data for Medical Device Pre-Market Registration: China’s NMPA Guidelines Explained

Each year, hundreds of medical device clinical trials are conducted outside China—from pulse oximeters to gene diagnostic kits—generating data that could accelerate access to innovative technologies for Chinese patients. But how does China’s National Medical Products Administration (NMPA) decide whether to trust this overseas data for pre-market registration? A 2021 guidance paper from the NMPA’s Center for Medical Device Evaluation breaks down the rules, balancing global collaboration with patient safety.

What Is “Overseas Clinical Trial Data”?

For the NMPA, overseas clinical trial data refers to results from studies done in other countries or regions that a device manufacturer wants to use to prove their product is safe and effective for sale in China. This includes both pre-market trials (done to get approval) and post-market trials (done after a device is on the market).

Core Principles for Accepting Overseas Data

The NMPA has three non-negotiable rules for overseas data. If any are violated, the data will not be accepted:

Ethical Compliance: Trials must follow the World Medical Association Declaration of Helsinki (the global gold standard for human research ethics) and the laws/regulations of the country where the trial was run. Sponsors must prove subjects’ rights, safety, and well-being were protected.
High-Quality Data: The trial must be conducted in a country with a robust clinical trial quality management system—like China’s Good Clinical Practice (GCP) standards. Even if local rules differ from China’s GCP, the data must still be authentic, reliable, and traceable.
Scientific Rigor: The trial must have a clear purpose, a well-designed protocol, and transparent results. Sponsors can’t cherry-pick data—they must submit all trial findings, not just positive ones.

“All three principles are mandatory,” write the authors (Shan Ju, Ying-Hui Liu, and colleagues from the NMPA’s clinical and biostatistics team). “Missing even one means the data won’t be used.”

Will Overseas Data Work for Chinese Patients?

A big question the NMPA asks is: Can results from foreign subjects be applied to Chinese users? Medical devices can act differently based on:

1. Patient Differences (Intrinsic & Extrinsic Factors)

Intrinsic factors: Biology like genetics, age, gender, or skin color. For example, a pulse oximeter (which uses light to measure oxygen levels) might be less accurate in Chinese patients if overseas trials only included people with lighter skin (melanin absorbs light, affecting readings).
Extrinsic factors: Lifestyle (diet, smoking), environment (pollution), or medical behavior (compliance with treatment). A gene diagnostic kit for a rare disease might fail in China if the overseas trial focused on mutation sites that are rare in Chinese populations.

In these cases, the NMPA may require a bridging study—a small trial or analysis to confirm the device works for Chinese patients.

2. Clinical Practice Differences

How a device is used matters too. Overseas trials might use different hospital protocols, equipment, or investigator skills. For example:

A surgical device that requires years of training might perform poorly in China if local surgeons haven’t learned to use it.
A diagnostic tool might not align with Chinese treatment guidelines if overseas trials followed different diagnostic criteria.

The NMPA checks whether these differences affect safety or effectiveness. If they do, sponsors might need to adjust the trial design or add Chinese data.

How the NMPA Uses Overseas Data

Overseas data can be part of a device’s clinical evaluation package—including the trial protocol, ethical review documents, and final report. Even if data meets all rules, the NMPA might ask for a supplementary trial (in China or abroad) to fill gaps. For example, if an overseas trial didn’t test a device in elderly patients (a large group in China), a follow-up study might be needed.

The NMPA also accepts data from comparable devices—marketed products with similar uses, design, and biology. If a new device is “similar enough” to one with proven safety data, that data can support the new device’s application.

Global Alignment & Patient Benefits

China’s rules are in line with other major regulators like the U.S. FDA, European Medicines Agency (EMA), and Japan’s PMDA—all of which accept overseas data when it’s ethical, high-quality, and relevant. The International Medical Device Regulators Forum (IMDRF) has also harmonized these standards, making it easier for companies to test devices globally.

The biggest win? Accepting overseas data reduces redundant trials. “This speeds up product launches and gets life-saving devices to patients faster,” the authors note.

What Sponsors Should Do

The NMPA recommends sponsors talk to the agency early—before starting trials—to agree on what data is needed. This avoids costly surprises later.

Final Takeaway

China’s approach to overseas clinical trial data isn’t about lowering standards—it’s about smartly using global evidence to benefit patients. By focusing on ethics, quality, and relevance, the NMPA ensures Chinese users get safe, effective devices without waiting for duplicate trials.

This article is based on research published in the Chinese Medical Journal (2021) by authors from the NMPA’s Center for Medical Device Evaluation.

doi: 10.1097/CM9.0000000000001595

Was this helpful?

0 / 0